However, in ovarian serous cystadenocarcinoma (OV) and glioblastoma multiforme (GBM), the chemotherapy responder group expressed higher RAD51 than the non-responder group (S-Figure 7C). This evidence concerns the gene RAD51 and glioblastoma.